Streetbeat News

Analyst Ratings

ACRX

AcelRx Pharmaceuticals reported Q2 earnings per share of $(0.40), beating the analyst consensus estimate of $(0.53) by 24.53%. This is a 66.67% increase over losses from the same period last year. The company also reported quarterly sales of $253.00K, beating the analyst consensus estimate of $70.00K by 261.43%, but this is a 55.61% decrease over sales from the same period last year.

Portfolio Pulse from vinayak@benzinga.com

August 10, 2023 | 8:39 pm

FREQ

Frequency Therapeutics reported Q2 losses of $(0.30) per share, beating the analyst consensus estimate of $(0.35) by 14.29%. This represents a 50.82% increase over losses from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:39 pm

DOOR

Stephens analyst Trey Grooms has reiterated an Overweight rating on Masonite International Corporation (NYSE:DOOR), raising the price target to $130 from $110. Despite a 3% decline in net sales in Q2 due to soft end-market demand, the company's EBITDA was ahead of expectations. The analyst expects Masonite's margins to expand due to cost reduction efforts and the realization of Endura acquisition synergies. However, the analyst has lowered sales estimates for Q3, FY23, and FY24 due to the challenging demand environment.

Portfolio Pulse from Nabaparna Bhattacharya

August 10, 2023 | 8:36 pm

WISH

ContextLogic Inc. (NASDAQ:WISH) shares fell on Thursday, continuing a trend that has seen the stock drop nearly 60% year-to-date. The company reported Q2 losses of $3.38 per share, beating analyst estimates, but missed on sales with $78 million against the expected $94.25 million. The company's board also approved a workforce reduction of 34%, causing the stock to trade lower. Loop Capital downgraded the stock from Hold to Sell and announced a $7 price target.

Portfolio Pulse from Ryan Gustafson

August 10, 2023 | 8:36 pm

DHR

A significant bearish stance has been taken on Danaher (NYSE:DHR) by a large investor, as indicated by unusual options activity. The overall sentiment of these big-money traders is split between 27% bullish and 72% bearish. The targeted price range for Danaher over the last 3 months is from $200.0 to $267.5. The current price of DHR is up 0.52% at $257.38. Analysts from Stifel, RBC Capital, Raymond James, and Barclays have maintained their ratings on Danaher, with price targets ranging from $240 to $292.

Portfolio Pulse from Benzinga Insights

August 10, 2023 | 8:33 pm

CXDO

Crexendo (NASDAQ:CXDO) reported Q2 earnings of $0.04 per share, beating the analyst consensus estimate of $0.01 by 300%. This is a 100% increase from the same period last year. The company also reported quarterly sales of $12.67 million, beating the analyst consensus estimate of $11.83 million by 7.10%. This is a 43.23% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:30 pm

SIEN

Sientra reported Q2 losses of $(0.85) per share, beating the analyst consensus estimate of $(0.86) by 1.16 percent. However, the company's quarterly sales of $23.13 million missed the analyst consensus estimate of $24.75 million by 6.55 percent.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:25 pm

EYEN

Eyenovia reported Q2 losses of $(0.16) per share, beating the analyst consensus estimate of $(0.17) by 5.88 percent. This is a 27.27 percent increase over losses of $(0.22) per share from the same period last year.

Portfolio Pulse from bharat@benzinga.com

August 10, 2023 | 8:16 pm

NWS

News Corp (NASDAQ:NWS) reported Q4 earnings of $0.14 per share, beating the analyst consensus estimate of $0.09 by 55.56%. However, the company's quarterly sales of $2.43 billion missed the analyst consensus estimate of $2.48 billion by 2.02%. This represents a 62.16% decrease in earnings and a 9.12% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:15 pm

HQI

HireQuest's Q2 earnings per share (EPS) of $0.15 missed the analyst consensus estimate of $0.28 by 46.43%, a 57.14% decrease from the same period last year. The company's quarterly sales of $8.99 million also missed the analyst consensus estimate of $10.37 million by 13.31%, a 3.21% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:14 pm